abstract: We assessed vaccine effectiveness (VE) against medically attended, laboratory-confirmed @entity683 in @entity1 6 months to 15 years of age in 22 hospitals in Japan during the 2013-14 season. Our study was conducted according to a test-negative case-control design based on @entity683 rapid diagnostic test (IRDT) results. Outpatients who came to our clinics with a fever of 38  C or over and had undergone an IRDT were enrolled in this study. @entity1 with positive IRDT results were recorded as cases, and @entity1 with negative results were recorded as controls. Between November 2013 and March 2014, a total of 4727 pediatric @entity1 (6 months to 15 years of age) were enrolled: 876 were positive for @entity683 , 66 for A(H1N1)pdm09 and in the other 810 the subtype was unknown; 1405 were positive for @entity1892 ; and 2445 were negative for @entity683 . Overall VE was 46% (95% confidence interval [CI], 39-52). Adjusted VE against @entity683 , @entity683 (H1N1)pdm09, and @entity1892 was 63% (95% CI, 56-69), 77% (95% CI, 59-87), and 26% (95% CI, 14-36), respectively. Influenza vaccine was not effective against either @entity683 or @entity1892 in @entity1 6 to 11 months of age. Two doses of @entity683 vaccine provided better protection against @entity281 than a single dose did. VE against hospitalization @entity281 was 76%. Influenza vaccine was effective against @entity683 , especially against @entity683 (H1N1)pdm09, but was much less effective against @entity1892 .

title: Effectiveness of Trivalent Inactivated Influenza Vaccine in XXXX Estimated by a Test-Negative Case-Control Design Study Based on Influenza Rapid Diagnostic Test Results.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'infants']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza', 'influenza A']

entities_list: @entity1892 :: ('MESH:D016393', 'Disease') :: ['influenza B']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['influenza A infection']

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: INTRODUCTION: Waist circumference does not distinguish subcutaneous from visceral adipose tissue, which is highly associated with @entity6 (T2DM). Because of the complexity of the assessment of visceral fat with imaging techniques, easy-to-apply and low-cost anthropometric measures have been proposed. The aim of the study was to show a possible association between Lipid Accumulation Product Index ( @entity26326 Index), Deep-abdominal adiposity tissue Index (DAAT) and @entity10478 Index (VAI) with metabolic profile and adipokines in @entity28 subjects with and without T2DM, and to compare the results with the use of waist circumference isolated. METHODS: In this cross-sectional study, we enrolled 101 outpatients with @entity28 (BMI >=  30 kg/m  ) of which 48% with @entity6 and aged 48.9   13.3 years. Demographic, clinical and anthropometric data were collected. Plasma @entity1851 , @entity650 , vascular adhesion molecule type 1 and @entity1254 levels, lipid profile and fasting @entity413 were assessed. @entity26326 Index, DAAT and VAI were @entity13738 was evaluated by bioelectric impedance analyses. Continuous variables were described as mean   standard deviation, and categorical variables as absolute numbers and percentages. Nonparametric data were log-transformed and Student's t test, Wilcoxon-Mann-Whitney and chi-squared test, Pearson correlation and multiple linear regression were used for statistical analyses. RESULTS: In total, 31 @entity1 and 70 @entity1 were evaluated. Individuals with T2DM showed higher @entity26326 values and percentage of body fat and lower waist circumference and BMI values. DAAT and @entity26326 were positively correlated with BMI, waist circumference, percentage of body fat and free fat mass. After adjustment for age, sex and total body fat, both @entity26326 Index and VAI were associated with plasma @entity1254 , LDL- @entity165 , non-HDL @entity165 and VLDL- @entity165 in @entity28 with and without T2DM (all P values  <= 0.02); fasting @entity413 remained associated with @entity26326 in @entity28 @entity1 without T2DM (P= 0.01). Waist circumference only correlated with @entity1254 in @entity28 subjects without T2DM (P= 0.048). CONCLUSIONS: Our data suggest that VAI and @entity26326 Index are good predictors of an impaired cardiometabolic setting in @entity28 regardless of T2DM status. Besides, we were not able to find associations with waist circumference and biochemical markers in our sample.

title: @entity10478 measurements, metabolic and inflammatory profile in @entity28 @entity1 with and without XXXX : a cross-sectional analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity10478 :: ('OMIM:155310', 'Disease') :: ['Visceral Adiposity']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'impaired cardiometabolic profile and type-2 diabetes mellitus']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

entities_list: @entity13738 :: ('MESH:C564221', 'Disease') :: ['calculated and body composition']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']

answer: @entity6 :: (MESH:D003920,Disease) :: ['type 2 diabetes mellitus']


abstract: BACKGROUND: Steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domains were first identified from @entity1 proteins that bind lipid/ @entity5068 ligands via a hydrophobic pocket. In plants, predicted START domains are predominantly found in homeodomain @entity368 zipper ( @entity2033 -Zip) transcription factors that are master regulators of cell-type differentiation in development. Here we utilized studies of @entity958 in parallel with heterologous expression of START domains in @entity375 to investigate the hypothesis that START domains are versatile ligand-binding motifs that can modulate transcription factor activity. RESULTS: Our results show that deletion of the START domain from @entity958 @entity35700 ( @entity35700 ), a representative @entity2033 -Zip transcription factor involved in differentiation of the epidermis, results in a complete loss-of-function phenotype, although the protein is correctly localized to the nucleus. Despite low sequence similarly, the @entity1 START domain from StAR can functionally replace the @entity2033 -Zip-derived START domain. Embedding the START domain within a synthetic transcription factor in @entity375 , we found that several @entity1 START domains from StAR, @entity50121 and @entity65592 stimulated transcription factor activity, as did START domains from two @entity958 @entity2033 -Zip transcription factors. Mutation of ligand-binding residues within StAR START reduced this activity, consistent with the @entity375 assay monitoring ligand-binding. The @entity65593 missense mutation in StAR START was shown to affect @entity35700 transcription factor activity in maintenance of the leaf trichome cell fate. Analysis of in vivo protein-metabolite interactions by mass spectrometry provided direct evidence for analogous lipid-binding activity in @entity1 and plant START domains in the @entity375 system. Structural modeling predicted similar sized ligand-binding cavities of a subset of plant START domains in comparison to @entity1 counterparts. CONCLUSIONS: The START domain is required for transcription factor activity in @entity2033 -Zip proteins from plants, although it is not strictly necessary for the protein's nuclear localization. START domains from both mammals and plants are modular in that they can bind lipid ligands to regulate transcription factor function in a @entity375 system. The data provide evidence for an evolutionarily conserved mechanism by which lipid metabolites can orchestrate transcription. We propose a model in which the START domain is used by both plants and mammals to regulate transcription factor activity.

title: Shared functions of plant and XXXX StAR-related lipid transfer (START) domains in modulating transcription factor activity.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian']

entities_list: @entity368 :: ('CHEBI:25017', 'Chemical') :: ['leucine']

entities_list: @entity958 :: ('3702', 'Species') :: ['Arabidopsis']

answer: @entity1 :: (9606,Species) :: ['mammalian']


abstract: PURPOSE: To examine whether objective performance of near tasks is improved with various electronic vision enhancement systems (EVES) compared with the subject's own optical magnifier. DESIGN: Experimental study, randomized, within- @entity1 design. METHODS: This was a prospective study, conducted in a hospital ophthalmology @entity4064 clinic. The @entity1 population comprised 70 sequential @entity227 subjects. The magnifying devices examined were: @entity1 's optimum optical magnifier; magnification and field-of-view matched @entity19 EVES with monitor or @entity135 ( @entity135 ) viewing; and stand EVES with monitor viewing. The tasks performed were: reading speed and acuity; time taken to track from one column of print to the next; follow a route map, and locate a specific feature; and identification of specific information from a medicine label. RESULTS: @entity19 EVES with @entity135 viewing caused lower reading speeds than stand EVES with monitor viewing (F = 38.7, P <.001). Reading with the optical magnifier was slower than with the @entity19 or stand EVES with monitor viewing at smaller print sizes (P <.05). The column location task was faster with the optical magnifier than with any of the EVES (F = 10.3, P <.001). The map tracking and medicine label identification task was slower with the @entity19 EVES with @entity135 viewing than with the other magnifiers (P <.01). Previous EVES experience had no effect on task performance (P >.05), but subjects with previous optical magnifier experience were significantly slower at performing the medicine label identification task with all of the EVES (P <.05). CONCLUSIONS: Although EVES provide objective benefits to the @entity227 in reading speed and acuity, together with some specific near tasks, some can be performed just as fast using optical magnification.

title: Benefits of electronic vision enhancement systems (EVES) for the XXXX .

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head-mounted display', 'HMD']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visually impaired']

answer: @entity227 :: (MESH:D014786,Disease) :: ['visually impaired']


abstract: @entity7131 ( @entity7131 ), a @entity141 /phospholipid-dependent protein kinase, is known as a key enzyme in various cellular responses, including apoptosis. However, the functional role of @entity7131 in apoptosis has not been clarified. In this study, we focused on the involvement of @entity4456 in @entity2367 -induced apoptosis in HeLa cells and examined the importance of spatiotemporal activation of the specific @entity7131 subtype in apoptotic events. @entity2367 -induced apoptosis was inhibited by the @entity4456 -specific inhibitor @entity12703 and also was blocked by knockdown of endogenous @entity4456 expression using small interfering RNA. @entity2367 induced the translocation of @entity4456 to the Golgi complex and the concomitant activation of @entity4456 via phosphorylation of Tyr(311) and Tyr(332) in the hinge region of the enzyme. Unphosphorylatable @entity4456 (mutants @entity62959 and @entity62960 ) could translocate to the Golgi complex in response to @entity2367 , suggesting that @entity669 phosphorylation is not necessary for translocation. However, @entity2367 failed to activate @entity4456 lacking the C1B domain, which did not translocate to the Golgi complex, but could be activated by @entity669 phosphorylation. These findings suggest that @entity2367 translocates @entity4456 to the Golgi complex and that @entity4456 is activated by @entity669 phosphorylation in the compartment. Furthermore, we utilized species-specific knockdown of @entity4456 by small interfering RNA to study the significance of phosphorylation of Tyr(311) and Tyr(332) in @entity4456 for @entity2367 -induced apoptosis and found that phosphorylation of Tyr(311) and Tyr(332) is indispensable for @entity2367 -induced apoptosis. We demonstrate here that the targeting mechanism of @entity4456 , dual regulation of both its activation and translocation to the Golgi complex, is critical for the @entity2367 -induced apoptotic event.

title: XXXX -induced apoptosis by translocation, phosphorylation, and activation of protein kinase Cdelta in the Golgi complex.

entities_list: @entity12703 :: ('MESH:C085746', 'Chemical') :: ['rottlerin']

entities_list: @entity7131 :: ('MESH:D020151', 'Disease') :: ['PKC', 'Protein kinase C']

entities_list: @entity2367 :: ('CHEBI:17761', 'Chemical') :: ['ceramide', 'Ceramide']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity2367 :: (CHEBI:17761,Chemical) :: ['Ceramide']


abstract: BACKGROUND: @entity43 ( @entity43 ) is the 5th leading cause of @entity5 around the world, and several chemotherapy regimens have been applied in the treatment of @entity43 . We aim to compare @entity137 of different chemotherapy regimens in the treatment of advanced @entity43 (AOC) using network meta-analysis. METHODS: Literature research in Cochrane Library, PubMed, and EMBASE was performed up to November 2015. Eligible @entity23 ( @entity23 ) of different chemotherapy regimens were included. Network meta-analysis combined direct and indirect evidence to assess pooled odds ratios (ORs) and draw the surface under the cumulative ranking (SUCRA) curves. RESULTS: Thirteen eligible @entity23 were included in this network meta-analysis, including 8 chemotherapy regimens ( @entity1311 + @entity3003 [PC], pegylated liposomal @entity632 [PLD]+ @entity3003 , @entity3003 , @entity136 + @entity3003 , @entity1311 , PC+ @entity1259 , PC+ @entity1945 , @entity1205 + @entity3003 ). @entity136 + @entity3003 regimen exerted higher incidence of @entity417 when compared with @entity3003 and @entity1311 regimens. The incidence of @entity1398 of @entity136 + @entity3003 regimen was higher than that of PC, PLD+ @entity3003 , @entity3003 , and PC+topotecan regimens. Topotecan PC+ @entity1259 regimen had a higher @entity137 , comparing with PC, PLD+ @entity3003 , and PC+topotecan regimens. As for @entity882 , @entity136 + @entity3003 chemotherapy regimen produced an obviously higher @entity137 than PC and @entity3003 . As for @entity390 , PLD+ @entity3003 chemotherapy regimen had a significantly higher @entity137 than that of @entity3003 chemotherapy regimen. Moreover, when compared with PC and @entity3003 chemotherapy regimens, the @entity137 of PC+ @entity1259 was greatly higher to @entity1 with AOC. CONCLUSION: The nonhematologic @entity137 of PLD+ @entity3003 regimen was higher than other regimens, which was clinically significant for the treatment of AOC.

title: @entity137 of different first-line chemotherapy regimens in the treatment of advanced XXXX : A network meta-analysis.

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'Ovarian cancer', 'OC']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities', 'toxicity']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-related deaths']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

entities_list: @entity23 :: ('MESH:D007174', 'Disease') :: ['RCTs', 'randomized controlled trials']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['febrile neutropenia']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']

entities_list: @entity1945 :: ('MESH:D019772', 'Chemical') :: ['topotecan']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']


abstract: STUDY DESIGN: A case report is presented. OBJECTIVES: Primary @entity5 of the rib are relatively uncommon in the adult population, and even more rare in @entity1 . A case of @entity421 of the rib and a literature review are presented. SUMMARY OF BACKGROUND DATA: @entity421 represents approximately 30% of all malignant @entity242 diagnosed in the United States. A single case of @entity421 of the rib has been reported in the literature involving a 9-year-old @entity1 . METHODS: Clinical data analysis. RESULTS: A 9-year-old white @entity1 presented with a mass of the left posterior thorax. The initial chest radiograph showed a nonhomogeneous mass with calcifications adjacent to the 11th rib. The final diagnosis was @entity421 . Chemotherapy was initiated. The @entity1 underwent radical excision of the mass. Given the extent of the @entity1 's resection, it was thought that he would be at high risk for the development of @entity85 . He was placed in a TLSO brace (Bolt Systems, Orlando, FL) and followed closely. At 15 months after excision of his @entity5 , he was noted to have progression of a @entity1635 and significant @entity1513 . At this writing, it has been 52 months since resection. The @entity1 has no evidence of local recurrence or @entity3 , and his spinal curvature remains stable. CONCLUSIONS: The @entity1 's short-term (4-year) disease-free survival illustrates the efficacy of neoadjuvant chemotherapy and radical surgical resection. @entity1 with @entity421 of the rib should be monitored closely for the development of @entity85 if the required resection includes the vertebral column. Casting and bracing may help to limit progression of the deformity.

title: XXXX of the rib: a case presentation and literature review.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patient', 'boy', 'child']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity1635 :: ('MESH:D012600', 'Disease') :: ['thoracolumbar scoliosis']

entities_list: @entity421 :: ('MESH:D012516', 'Disease') :: ['osteogenic sarcoma', 'Osteogenic sarcoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['spinal deformity']

answer: @entity421 :: (MESH:D012516,Disease) :: ['Osteogenic sarcoma']


abstract: (n-3) @entity1718 may reduce the risk of @entity944 by preventing life-threatening @entity943 . A standard electrocardiogram (ECG) may be used to detect clues as to the mechanism by which (n-3) @entity1718 affect the electrophysiology of the heart. An earlier study showed that (n-3) @entity1718 decreased the duration of the heart-rate corrected QT interval (QTc) in @entity235 . However, effects of (n-3) @entity1718 on the standard ECG of @entity1 have not been reported. Therefore, we investigated the effect of (n-3) @entity1718 on QTc, QRS duration, apex-to-end-T duration, T-loop morphology and spatial QRS- @entity20576 in apparently healthy @entity1 and @entity1 aged 50 to 70 y. Subjects (n = 42/group) received either capsules providing 1.5 g (n-3) @entity1718 daily or placebo for 12 wk. ECG were recorded before and after intervention. None of the ECG characteristics were affected by (n-3) @entity1718 . The QTc decreased by 0.8 ms or 0.2% (95% confidence interval, -6.1 to 4.4 ms) in subjects that consumed (n-3) @entity1718 compared with the placebo group. These results do not support the hypothesis that (n-3) @entity1718 prevent @entity943 through electrophysiologic effects on heart cell membranes. However, an effect on the ECG in more susceptible populations can not be excluded.

title: (N-3) fatty acids do not affect electrocardiographic characteristics of healthy @entity1 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'humans', 'men']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['cardiac arrhythmia', 'arrhythmia']

entities_list: @entity944 :: ('MESH:D003645', 'Disease') :: ['sudden death']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['Fatty acids', 'fatty acids']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: BACKGROUND AND AIMS: Information comparing treatment outcome for diffuse large B  cell ( @entity4812 ) and @entity7979 ( @entity7979 ) @entity1893 ( @entity1893 ) @entity1 treated with schemes with and without rituximab from low- and middle-income countries is scarce. Clinical characteristics, response to therapy and long-term outcome of @entity4812 and @entity7979 @entity1 were studied. METHODS: @entity1 with @entity4812 and @entity7979 diagnosed over 8  years at a reference center in northeast Mexico were included. Kaplan-Meier method was used to determine @entity1349 ( @entity1349 ) and @entity1349 ( @entity1349 ). Cox regression model was used to evaluate the association between risk factors, rituximab therapy and clinical outcome. RESULTS: One hundred-sixteen @entity1 with @entity4812 and 65 with @entity7979 in advanced stages were included. Median age was 57.8 and 56  years, respectively. Clinical characteristics between groups receiving or not receiving rituximab were comparable. Stages III and IV were found in 63.8% of @entity4812 and 84.6% in @entity7979 @entity1 , respectively. @entity1349 and @entity1349 at 60  months were 63.8 and 51.2% in @entity4812 and 70.6 and 33.8% in @entity7979 . No difference in @entity1349 was found in @entity4812 and @entity7979 when rituximab-based regimens vs. non rituximab-based regimens were compared, but a statistically significant difference was documented in @entity1349 in @entity7979 @entity1 . CONCLUSION: Addition of rituximab to @entity3726 -like regimens did not improve @entity1349 in @entity4812 and @entity7979 @entity1893 subtypes. In comparison to developed countries, diagnosis of @entity1893 was made a decade earlier and in advanced clinical stages. Cost-efficiency of adding @entity2408 to therapy for these @entity1 should be assessed.

title: XXXX : Impact of Rituximab on Overall Survival of @entity1 with Diffuse Large B-Cell and Follicular Lymphoma.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2408 :: ('CHEBI:64357', 'Chemical') :: ['rituximab']

entities_list: @entity7979 :: ('MESH:D005497', 'Disease') :: ['FL', 'follicular']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ['NHL', 'non-Hodgkin lymphoma']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'PFS', 'overall survival', 'progression-free survival']

answer: @entity1893 :: (MESH:D008228,Disease) :: ['Non-Hodgkin Lymphomas']


abstract: AIMS: To evaluate renal morphology, prevalence of @entity28739 , renal perfusion and resistance to renal blood flow in @entity1 with @entity1691 ( @entity5427 ). MATERIAL AND METHODS: Thirty-eight @entity1 diagnosed with @entity5427 and with normal basal renal functions, together with 38 healthy individuals matched in terms of age, sex, blood lipid profile and body mass index, were included. Total @entity165 , @entity412 , @entity1133 , @entity1011 and @entity413 levels were measured in both groups, as well as @entity560 , erythrocyte sedimentation rate (ESR) and C-reactive protein in the @entity5427 group. Renal dimensions, parenchymal echogenicity, presence of stone and renal resistive index (RRI) from the interlobular artery level were measured, and correlations with clinical and laboratory parameters were assessed. RESULTS: Thirty-eight @entity1 diagnosed with @entity5427 (age 42.4+/- 11.5, 24 male, 14 @entity1 ) and a control group of 38 healthy individuals (age 41.7+/-10.8, 23 male, 15 female) were included in the study. @entity1290 was present in 7 @entity1 (18.4%) in the @entity5427 group and 4 subjects (10.5%) in the control group. There was no significant difference in prevalence of stone between the groups (p=0.516). RRI values were significantly higher in the @entity1 with @entity5427 (0.63+/-0.06) compared with the control group (0.59+/-0.03, p=0.001). Significant correlations were determined between RRI and age, @entity412 level, body mass index and length of disease. CONCLUSIONS: Renal Doppler is an important examination in early diagnosis and monitoring of renal changes in @entity5427 @entity1 since @entity8 in @entity5427 develop in the chronic and follow a subclinical course.

title: Prospective evaluation of the renal morphology and vascular resistance in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal complications']

entities_list: @entity28739 :: ('MESH:D014545', 'Disease') :: ['urinary stone disease']

entities_list: @entity1691 :: ('MESH:D013167', 'Disease') :: ['ankylosing spondylitis']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity1290 :: ('MESH:D007669', 'Disease') :: ['Renal stone']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

entities_list: @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']

answer: @entity1691 :: (MESH:D013167,Disease) :: ['ankylosing spondylitis']


abstract: BACKGROUND: Viral kinetic models have proven useful to characterize treatment effectiveness during @entity3531 therapy with interferon (IFN) or with direct-acting antivirals. METHODS: We use a pharmacokinetic/viral kinetic (PK/VK) model to describe @entity3531 RNA kinetics during treatment with @entity65535 , a protease inhibitor. In a Phase I study, @entity65535 monotherapy was administered for 14 days in ascending doses ranging from 200 to 600 mg per day to 40 @entity1 of whom 32 were treatment-naive and 8 were non-responders to prior pegylated @entity686 /ribavirin treatment. RESULTS: In all @entity1 , a biphasic decline of @entity3531 RNA during therapy was observed. A two-compartment PK model and a VK model that considered treatment effectiveness to vary with the predicted @entity65535 concentration inside the second compartment provided a good fit to the viral load data. A time-varying effectiveness model was also used to fit the viral load data. The antiviral effectiveness increased in a dose-dependent manner, with a 14-day time-averaged effectiveness of 0.95 at the lowest dose (100 mg twice daily) and 0.99 at the highest dose (200 mg three times daily). Prior IFN non-responders exhibited a 14-day time-averaged effectiveness of 0.98 (300 mg twice daily). The second phase decline showed two different behaviours, with 30% of @entity1 exhibiting a rapid decline of @entity3531 RNA, comparable to that seen with other protease inhibitors (>0.3 day(-1)), whereas the viral decline was slower in the other @entity1 . CONCLUSIONS: Our results are consistent with the modest SVR rates from the INFORM-SVR study where @entity1 were treated with a combination of @entity65536 and @entity486 -boosted @entity65535 .

title: A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of @entity65535 against chronic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity65535 :: ('MESH:C553752', 'Chemical') :: ['danoprevir']

entities_list: @entity65536 :: ('MESH:C552098', 'Chemical') :: ['mericitabine']

entities_list: @entity486 :: ('MESH:D019438', 'Chemical') :: ['ritonavir']

answer: @entity3531 :: (11096,Species) :: ['HCV']


abstract: Objective:: To evaluate the safety and feasibility of the use of indwelling pleural catheters (IPCs) in @entity1 with @entity3483 ( @entity3483 ). Methods:: We prospectively collected data from @entity1 with @entity3483 undergoing IPC placement between January of 2014 and July of 2015. All @entity1 submitted to IPC placement had a life expectancy > 30 days, in accordance with the @entity3483 treatment guidelines established by the British @entity1514 Society. The data collected included gender, age, body mass index, primary @entity5 site, duration of IPC drainage, IPC-related complications, length of hospital stay, @entity1143 recurrence, and occurrence of spontaneous pleurodesis. Results:: A total of 19 @entity1 underwent IPC placement during the study period. Median overall survival after IPC insertion was 145 days. The median follow-up among the surviving @entity1 was 125 days (range, 53-485 days), and the median time between catheter insertion and removal was 31 days (range, 2-126 days). There were IPC-related complications in 5 @entity1 (26.2%), and spontaneous pleurodesis was achieved in 8 (42.0%). Among those 8 @entity1 , the IPC was removed between days 30 and 126 in 4, and spontaneous pleurodesis occurred within the first 30 days in 4. Conclusions:: The use of IPCs seems to be feasible and safe in @entity1 with @entity3483 . Objetivo:: Avaliar a seguran  a e a viabilidade do uso de cateter @entity2319 (CPLP) em pacientes com derrame pleural neopl  sico (DPN). M  todos:: Dados referentes a pacientes com DPN que receberam CPLP entre janeiro de 2014 e julho de 2015 foram colhidos prospectivamente. Todos os pacientes que receberam CPLP tinham expectativa de vida > 30 dias, em conformidade com as diretrizes de tratamento de DPN da Sociedade Tor  cica Brit  nica. Foram colhidos dados sobre sexo, idade,   ndice de massa corporal, local do c  ncer prim  rio, tempo de drenagem com o CPLP, complica    es relacionadas com o CPLP, tempo de interna    o hospitalar, recidiva do derrame pleural e ocorr  ncia de pleurodese espont  nea. Resultados:: Dezenove pacientes receberam CPLP durante o per  odo de estudo. A mediana de sobrevida global ap  s a inser    o do CPLP foi @entity66533 dias. A mediana de tempo de acompanhamento dos pacientes sobreviventes foi de 125 dias (varia    o: 53-485 dias), e a mediana de tempo decorrido entre a inser    o e a remo    o do cateter foi de 31 dias (varia    o: 2-126 dias). Houve complica    es relacionadas com o CPLP em 5 pacientes (26,2%) e pleurodese espont  nea em 8 (42,0%). Nesses 8 pacientes, o CPLP foi retirado entre os dias 30 e 126 em 4, e a pleurodese espont  nea ocorreu nos primeiros 30 dias em 4. Conclus  es:: O uso de CPLP parece ser vi  vel e seguro em pacientes com DPN.

title: Use of indwelling pleural catheters for the definitive treatment of XXXX .

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity2319 :: ('MESH:D003638', 'Disease') :: ['pleural de longa perman  ncia']

entities_list: @entity3483 :: ('MESH:D016066', 'Disease') :: ['MPE', 'malignant pleural effusion']

answer: @entity3483 :: (MESH:D016066,Disease) :: ['malignant pleural effusion']


abstract: In a @entity19 model of @entity1614 , conventional Verhoeff-Van Gieson staining displays severe @entity1949 , disorganization and loss of the aortic elastic fiber integrity. However, this method involves chemical fixatives and staining, which may alter the native morphology of @entity20616 and collagen. Thus far, quantitative analysis of fiber damage in aorta and skin in @entity1614 has not yet been explored. In this study, we have used an advanced noninvasive and label-free imaging technique, multiphoton microscopy to quantify fiber @entity1949 , disorganization, and total volumetric density of aortic and cutaneous @entity20616 and collagen in a @entity19 model of @entity1614 . Aorta and skin samples were harvested from Marfan and control @entity19 aged 3-, 6- and 9-month. @entity20616 and collagen were identified based on two-photon excitation fluorescence and second-harmonic-generation signals, respectively, without exogenous label. Measurement of fiber length indicated significant @entity1949 in Marfan vs. control. Fast Fourier transform algorithm analysis demonstrated markedly lower fiber organization in Marfan @entity19 . Significantly reduced volumetric density of @entity20616 and collagen and thinner skin dermis were observed in Marfan @entity19 . Cutaneous content of elastic fibers and thickness of dermis in 3-month Marfan resembled those in the oldest control @entity19 . Our findings of early signs of fiber degradation and thinning of skin dermis support the potential development of a novel non-invasive approach for early diagnosis of @entity1614 .

title: Quantification of aortic and cutaneous XXXX and collagen morphology in @entity1614 by multiphoton microscopy.

entities_list: @entity1614 :: ('MESH:D008382', 'Disease') :: ['Marfan syndrome']

entities_list: @entity1949 :: ('MESH:D012892', 'Disease') :: ['fragmentation']

answer: @entity20616 :: (13717(Tax:10090),Gene) :: ['elastin']


abstract: The Revised National Tuberculosis Control Programme (RNTCP), based on the World Health Organization's DOTS strategy,* was introduced in India in the mid-1990s. This paper reports the findings from operational research studies in two pilot sites in New Delhi from 1996 to 1998. A variety of operational research methods were used, including semi-structured interviews, focus group discussions, non- @entity1 observations and collection of data from the @entity378 registers. The cure rates for the clinics were 71 and 75% with a default rate of 6 and 11%, respectively. An important finding was that health workers screened @entity1 to determine their ability to conform to the direct observation of treatment element of the RNTCP. If the health worker was confident that the @entity1 would comply and/or be easy to trace in the community in the event of 'default', they were provided with short-course treatment under the RNTCP. Other @entity1 , largely those who were in absolute poverty, socially marginalized, itinerant labourers, poorly integrated in the city, were put on standard @entity378 ( @entity378 ) treatment as for the previous National @entity378 Programme. The programme was evidently excluding the most vulnerable from the best available care. These findings demonstrate the potential dangers of target-driven programmes where there is an absence of support to both frontline health workers and @entity1 . The paper also highlights the importance of operations research in helping to identify problems within @entity378 programmes.

title: XXXX control, poverty, and vulnerability in Delhi, India.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'participant', 'patient']

entities_list: @entity378 :: ('MESH:D014376', 'Disease') :: ['TB', 'tuberculosis']

answer: @entity378 :: (MESH:D014376,Disease) :: ['TB']


abstract: Fifty-seven @entity1 were examined with CT 5 years after primary myelography for disabling sciatica and suspected @entity890 . Forty were in an operated group, 22 with good and 18 with poor results evaluated by occupational handicap (21) 5 years after surgery. Seventeen @entity1 had myelography indicating disk herniation, but were treated conservatively, 9 with good and 8 with poor result. Various spinal dimensions measured at CT did not correlate with outcome. Operated @entity1 had narrower canals than others, and male canals were broader than those in females. Increased amount of scar tissue at L4 level correlated with poor result (p = 0.008). Operated @entity1 with poor result had more advanced lateral stenosis than those treated conservatively (p less than 0.001). @entity1 with good result after operation had more degeneration observed on CT of erector spinae muscle than those treated conservatively with good outcome. Only 9% of operated @entity1 did not have @entity121 . A tendency for more frequent recurrent disk herniations could be seen for conservatively treated @entity1 . The narrowing of the spinal canal 5 years after operation did not correlate with the 5-year outcome.

title: CT five years after myelographic diagnosis of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['muscle degeneration']

entities_list: @entity890 :: ('MESH:D007405', 'Disease') :: ['herniated lumbar disk']

answer: @entity890 :: (MESH:D007405,Disease) :: ['lumbar disk herniation']


abstract: UNASSIGNED: A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantitation of the antimalarial drug, @entity15281 (LF), in @entity19 whole blood and plasma. The analyte was extracted using a protein precipitation method followed by chromatographic separation on a Phenomenex Luna, PFP (50mm*2.0mm, 5 m) analytical column with a mobile phase consisting of @entity1626 and 0.1% @entity5189 ( @entity5189 :water, 1:1000, v/v) at a ratio of 3:7 (v/v), delivered at a constant flow rate of 0.5ml/min. Stable isotope labeled @entity15281 (D9-LF) was used as the internal standard. Multiple reaction monitoring was performed using the transitions m/z 530.1 > m/z 347.9 and m/z 539.1 > m/z 347.9 for the quantification of LF and D9-LF, respectively. Calibration curves were constructed over the concentration range 15.6-4000ng/ml. The mean intra- and inter-assay accuracy values for the analysis of LF in WB was 103% (%CV=5.5) and 99.5% (%CV=5.5), respectively. The mean intra- and inter-assay accuracy values for the analysis of LF in plasma was 93.7% (%CV=3.5) and 93.9% (%CV=5.5), respectively. No significant matrix effect was observed during the method validation. The validated method was applied to an absorption study in @entity19 , to determine and compare LF concentrations in whole blood and plasma samples. Results of the statistical analysis using a linear mixed effects growth curve model concluded that there was no significant difference (p-value=0.668) between WB and plasma LF concentrations. This method utilizes a small sample volume of 20 l, facilitating low blood collection volumes and a short chromatographic run time of 3min which allows for high sample throughput analysis.

title: Development and validation of a LC-MS/MS method for the quantitation of XXXX in @entity19 whole blood and plasma.

entities_list: @entity15281 :: ('MESH:C102070', 'Chemical') :: ['lumefantrine']

entities_list: @entity5189 :: ('MESH:C030544', 'Chemical') :: ['formic acid']

entities_list: @entity1626 :: ('MESH:C032159', 'Chemical') :: ['acetonitrile']

answer: @entity15281 :: (MESH:C102070,Chemical) :: ['lumefantrine']


abstract: UNASSIGNED: @entity14151 (SGIV) is a major viral pathogen of grouper aquaculture, and has caused heavy economic losses in China and Southeast Asia. In this study, we generated four single-stranded DNA aptamers against SGIV-infected @entity1358 ( @entity1358 ) using systematic evolution of ligands by exponential enrichment technology (SELEX). Four aptamers exhibited high affinity to SGIV-infected @entity1358 cells, in particular the Q2 aptamer. Q2 had a binding affinity of 12.09 nM, the highest of the four aptamers. These aptamers also recognized SGIV-infected tissues with high levels of specificity. Protease treatment and flow cytometry analysis of SGIV-infected cells revealed that the target molecules of the Q3, Q4, and Q5 aptamers were trypsin-sensitive proteins, while the target molecules of Q2 might be membrane lipids or surface proteins that were not trypsin-sensitive. The generated aptamers appeared to inhibit SGIV infection in vitro. Aptamer Q2 conferred the highest levels of protection against SGIV, and was able to inhibit SGIV infection in a dose-dependent manner. In addition, Q2 was efficiently internalized by SGIV-infected @entity1358 cells and localized at the viral assembly sites. Our results demonstrate that the four novel aptamers we generated were specific for SGIV infected cells, and could potentially be applied as rapid molecular diagnostic test reagents or therapeutic drugs targeting SGIV.

title: Selection and characterization of the novel DNA-aptamers specifically recognized XXXX (SGIV) infected fish cells.

entities_list: @entity14151 :: ('262968', 'Species') :: ['Singapore grouper iridovirus']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['grouper spleen cells', 'GS']

answer: @entity14151 :: (262968,Species) :: ['Singapore grouper iridovirus']


abstract: Calmodulin is a @entity460 ion-sensing signalling protein found in eukaryotics. Two calmodulin-like gene sequences were identified in an EST library from adult @entity8072 . One codes for a protein (FhCaM1) homologous to @entity1 calmodulins (98% identity), whereas the other protein (FhCaM2) has only 41% identity. These genes were cloned into expression vectors and the recombinant proteins were expressed in @entity526 . Gel shift assays showed that both proteins bind to @entity460 , @entity1760 and @entity219 ions. Homology models have been built for both proteins. As expected, FhCaM1 has a highly similar structure to other calmodulins. Although FhCaM2 has a similar fold, its surface charge is higher than FhCaM1. One of the potential metal ion-binding sites has lower metal-ion co-ordination capability, while another has an adjacent @entity376 residue, both of which may decrease the metal-binding affinity. These differences may reflect a specialised role for FhCaM2 in the @entity8072 .

title: Characterisation of two calmodulin-like proteins from the @entity8072 , XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian']

entities_list: @entity376 :: ('CHEBI:25094', 'Chemical') :: ['lysine']

entities_list: @entity8072 :: ('6192', 'Species') :: ['liver flukes', 'liver fluke']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli']

entities_list: @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']

answer: @entity8072 :: (6192,Species) :: ['Fasciola hepatica']


abstract: BACKGROUND:    @entity1 infected with @entity778 present with @entity647 ( @entity647 ) that is due to severe @entity55 and systemic @entity32 . It is often fatal because there are few effective treatment options. Complement activation has been implicated in the pathogenesis of virus-induced @entity651 ; therefore, we investigated the effect of targeted complement inhibition on @entity647 induced by @entity778 . METHODS:    A novel neutralizing specific antihuman C5a antibody (IFX-1) was used. This antibody blocked the ability of C5a to induce granulocytes to express CD11b while not affecting the ability of C5b to form the membrane attack complex. @entity3176 were inoculated with H7N9 virus and treated intravenously with IFX-1. RESULTS:    The virus infection led to intense @entity647 and @entity1850 ( @entity1850 ) in association with excessive complement activation. Anti-C5a treatment in H7N9-infected monkeys substantially attenuated @entity647 : It markedly reduced the lung histopathological injury and decreased the lung infiltration of macrophages and neutrophils. Moreover, the treatment decreased the intensity of @entity1850 ; the body temperature changes were minimal and the plasma levels of inflammatory mediators were markedly reduced. The treatments also significantly decreased the virus titers in the infected lungs. CONCLUSIONS:    Antihuman C5a antibody treatment remarkably reduced the @entity647 and systemic @entity32 induced by @entity778 . Complement inhibition may be a promising adjunctive therapy for severe @entity5131 .

title: Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients']

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['influenza A(H7N9) virus', 'H7N9 virus infection']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity5131 :: ('MESH:D011024', 'Disease') :: ['viral pneumonia']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity651 :: ('MESH:D055370', 'Disease') :: ['lung injury']

entities_list: @entity1850 :: ('MESH:D018746', 'Disease') :: ['systemic inflammatory response syndrome', 'SIRS']

entities_list: @entity3176 :: ('9534', 'Species') :: ['African green monkeys']

entities_list: @entity647 :: ('MESH:D055371', 'Disease') :: ['acute lung injury', 'ALI']

answer: @entity3176 :: (9534,Species) :: ['African Green Monkeys']


abstract: OBJECTIVES: We studied the clinical features of @entity1121 ( @entity1121 ) caused by a novel mutation in the @entity18963 ( @entity18963 ) gene in @entity1 and family members of Japanese descent. BACKGROUND: Previous reports have demonstrated that the clinical features of @entity1121 associated with mutations in the @entity18963 gene include late onset and a favorable clinical course. Recently, some mutations in genes encoding sarcomeric proteins have been reported to be a cause of @entity384 ( @entity384 ), as well as @entity1121 . However, mutations of the @entity18963 gene have not been reported as a cause of @entity384 up to now. METHODS: We analyzed @entity18963 gene mutations in 250 unrelated probands with @entity1121 and in 90 with @entity384 . We used electrocardiography (ECG) and echocardiography to determine clinical phenotypes. RESULTS: We identified 17 individuals in 8 families (7 @entity1121 , 1 @entity384 ) with an @entity67274 mutation in the @entity18963 gene. Overall, 2 (40%) of 5 carriers age >70 years displayed "burnt-out" phase @entity1121 , and one of them had been diagnosed as having @entity384 before genetic identification. The disease penetrance in subjects age >50 years was 70% by echocardiography and 100% by ECG, and that in those age <50 years was 40% and 50%, respectively. CONCLUSIONS: Elderly @entity1 with @entity67274 mutation may show "burnt-out" phase @entity1121 , and @entity1 with this mutation may be included among those diagnosed as having @entity384 . Screening of @entity1 with @entity384 , as well as @entity1121 , for this mutation is of significant importance because @entity1 with this mutation may be diagnosed clinically as having @entity384 .

title: A novel missense mutation in the XXXX gene is responsible for @entity1121 with left ventricular dysfunction and dilation in elderly @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['DCM', 'dilated cardiomyopathy']

entities_list: @entity18963 :: ('4607', 'Gene') :: ['MyBP-C', 'myosin binding protein-C']

entities_list: @entity67274 :: ('p|SUB|R|820|Q', 'ProteinMutation') :: ['Arg820Gln']

entities_list: @entity1121 :: ('MESH:D002312', 'Disease') :: ['HCM', 'hypertrophic cardiomyopathy']

answer: @entity18963 :: (4607,Gene) :: ['myosin binding protein-C']


abstract: BACKGROUND: The genetic basis of @entity33949 ( @entity33949 ) is different and is explained by mutations in the @entity9379 ( @entity9379 ) gene. However, mutated @entity9379 does not account for the disease in all the @entity1 , neither does it explain the phenotypic heterogeneity between @entity33949 and @entity6 ( @entity6 ). Recent studies suggest a crucial role for pancreatic @entity916 -angiotensin system during chronic @entity519 in acute @entity788 and for @entity1289 ( @entity1289 ) inhibitors in reducing pancreatic @entity82 in experimental models. We investigated the association of @entity1289 gene insertion/deletion (I/D) polymorphism in @entity33949 @entity1 using a case-control approach. Since @entity9379 mutations are proposed a modifier role, we also investigated its interaction with the @entity1289 gene variant. METHODS: We analyzed the I/D polymorphism in the @entity1289 gene ( @entity65869 ) in 171 subjects comprising 91 @entity33949 and 80 @entity6 @entity1 and compared the allelic and genotypic frequency in them with 99 healthy ethnically matched control subjects. RESULTS: We found 46% and 21% of @entity33949 @entity1 , 56% and 19.6% of @entity6 @entity1 and 54.5% and 19.2% of the healthy controls carrying the I/D and D/D genotypes respectively (P>0.05). No significant difference in the clinical picture was observed between @entity1 with and without the del allele at the @entity1289 in/del polymorphism in both categories. No association was observed with the presence or absence of @entity20619 @entity9379 mutation in these @entity1 . CONCLUSION: We conclude that the @entity1289 insertion/deletion variant does not show any significant association with the pathogenesis, @entity82 and progression of @entity33949 and the @entity6 .

title: Lack of significant association of an insertion/deletion polymorphism in the XXXX ( @entity1289 ) gene with @entity33949 .

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity1289 :: ('1636', 'Gene') :: ['angiotensin converting enzyme', 'ACE']

entities_list: @entity20619 :: ('p|SUB|N|34|S', 'ProteinMutation') :: ['N34S']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['fibro-calculous pancreatic diabetes', 'FCPD']

entities_list: @entity9379 :: ('6690', 'Gene') :: ['SPINK1', 'pancreatic secretory trypsin inhibitor']

entities_list: @entity33949 :: ('MESH:C564276', 'Disease') :: ['TCP', 'tropical calcific pancreatitis']

answer: @entity1289 :: (1636,Gene) :: ['angiotensin converting enzyme']


abstract: OBJECTIVES: The purpose of this study was to examine the relationship between the origin and breakout site of idiopathic @entity1165 ( @entity1165 ) or @entity1540 ( @entity1540 ) originating from the myocardium around the ventricular outflow tract. BACKGROUND: The myocardial network around the ventricular outflow tract is not well known. METHODS: We studied 70 @entity1 with idiopathic @entity1165 (n = 23) or @entity1540 (n = 47) with a @entity714 and inferior QRS axis morphology. Electroanatomical mapping was performed in both the right ventricular outflow tract (RVOT) and aortic sinus cusp (ASC) during @entity1165 or @entity1540 . RESULTS: The @entity67 ( @entity67 ) was recorded in the RVOT in 55 @entity1 (group R) and in the ASC in 15 (group A). In all group R @entity1 , the closest pace map and successful ablation were achieved at the @entity67 site. Although a successful ablation was achieved at the @entity67 site in all group A @entity1 , the closest pace map was obtained at the @entity67 site in 8 and RVOT in 7 (with an excellent pace map in 4). The stimulus to QRS interval was 0 ms during pacing from the RVOT and 36 +/- 8 ms from the ASC. The distance between the @entity67 and perfect pace map sites in those 4 @entity1 was 11.9 +/- 3.0 mm. CONCLUSIONS: @entity943 originating from the ASC often show preferential conduction to the RVOT, which may render pace mapping or some algorithms using the electrocardiographic characteristics less reliable. In some of those cases, an insulated myocardial fiber across the ventricular outflow septum may exist.

title: Preferential conduction across the ventricular outflow septum in XXXX originating from the aortic sinus cusp.

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['VT', 'ventricular tachycardia']

entities_list: @entity714 :: ('MESH:D002037', 'Disease') :: ['left bundle branch block']

entities_list: @entity1540 :: ('MESH:D018879', 'Disease') :: ['premature ventricular contractions', 'PVCs']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['earliest ventricular activation', 'EVA']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['Ventricular arrhythmias']

answer: @entity943 :: (MESH:D001145,Disease) :: ['ventricular arrhythmias']


abstract: Here we present a male @entity1 with @entity3052 ( @entity3052 ) initially diagnosed as M5 and with karyotype 46,XY. After induction therapy, he underwent a HLA-matched allogeneic hematopoietic stem cell transplantation, and six years later he relapsed as @entity3052 with an abnormal karyotype //47,XX,+10[2]/47,XX,+11[3]/48,XX,+10,+11[2]/46,XX[13]. Based on this, we tested the possibility of donor cell origin by FISH and molecular STR analysis. We found no evidence of Y chromosome presence by FISH and STR analysis consistent with the success of the allogeneic hematopoietic stem cell transplantation from the female donor. FISH studies confirmed trisomies and no evidence of @entity11626 translocation either @entity876 or @entity14050 deletion. Additionally 28 fusion common @entity1778 transcripts were evaluated by multiplex reverse transcriptase-polymerase chain reaction assay and were not rearranged. STR analysis showed a complete donor chimerism. Thus, donor cell @entity1778 (DCL) was concluded, being essential the use of cytological and molecular approaches. Pediatric DCL is uncommon, our @entity1 seems to be the sixth case and additionally it presented a late donor cell @entity1778 appearance. Different extrinsic and intrinsic mechanisms have been considered to explain this uncommon finding as well as the implications to the @entity1 .

title: Pediatric donor cell leukemia after allogeneic hematopoietic stem cell transplantation in @entity3052 XXXX from related donor.

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML M1', 'AML']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: OBJECTIVE: The proximal aortic neck remains one of the challenges of @entity439 repair (EVAR), and the risk of type Ia endoleak and endograft migration is increased in @entity1 with short, large-diameter, or highly angulated necks. EndoAnchors have been used as an adjunct to EVAR in such @entity1 , and the aim of this study was to assess their benefit analyzed by indication for use. METHODS: During a 2-year period, 319 @entity1 were enrolled at 43 sites in the @entity439 Treatment Using the Heli-FX Aortic Securement System Global Registry (ANCHOR) study. This prospective, multinational, real-world analysis of EndoAnchors comprised two groups of @entity1 , those undergoing first-time EVAR (primary arm, 242) and those with proximal neck complications remote from the time of an initial endograft implantation (revision arm, 77). The primary arm was further subdivided into @entity1 undergoing prophylactic EndoAnchor use for hostile proximal neck anatomy (178), with a type Ia endoleak evident during initial endograft deployment (60), and in conjunction with extender cuffs after unsatisfactory endograft deployment distally in the neck (four). The revision arm was subdivided into @entity1 presenting with a type Ia endoleak alone (45), endograft migration alone (11), and migration with endoleak (21). Technical success was site reported as satisfactory deployment of the desired number of EndoAnchors without @entity174 or loss of integrity. Procedural success was defined as technical success without type Ia endoleak at completion arteriography. Core laboratory analysis was performed on 249 baseline and 192 follow-up computed tomographic studies, 66 of which were available within the 1-year window. RESULTS: Technical and procedural success rates were highest in the prophylactically treated subset (172 of 178; 96.6%). Whereas the technical success of EndoAnchor deployment was also high in the other subsets, residual type Ia endoleaks were more frequent at completion angiography when the indication for EndoAnchor use was type Ia endoleak, both in the primary arm (17 of 60; 28%) and in the revision arm (9 of 45; 20%). During a median imaging follow-up of 7 months, 183 of 202 @entity1 (90.1%) remained free of type Ia endoleaks. Primary prophylactic @entity1 were free from type Ia endoleak in 110 of 114 cases (96.5%). The most challenging subset was revision @entity1 treated for type Ia endoleak; type Ia endoleaks were evident during follow-up in 10 of 29 of the cases (34%). Sac regression >5 mm in @entity1 with 1-year imaging was observed in 26 of 66 @entity1 (39%) and was highest in the primary prophylaxis subset (20 of 43; 47%). CONCLUSIONS: EndoAnchor implantation can be a useful adjunct to EVAR as prophylaxis against proximal attachment site complications in @entity1 with hostile aortic neck anatomy, as treatment for early and late type Ia endoleaks, or, in conjunction with aortic extension cuffs, for endograft migration. Whereas the most challenging @entity1 are those who present with type Ia endoleaks remote from initial EVAR, EndoAnchors are still effective in treating the majority of these cases.

title: Analysis of EndoAnchors for XXXX repair by indications for use.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['endovascular aneurysm', 'Aneurysm']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

answer: @entity439 :: (MESH:D000783,Disease) :: ['endovascular aneurysm']


abstract: INTRODUCTION: Several bone graft materials have been used in the treatment of @entity154 . Demineralized freeze-dried bone allograft (DFDBA) has been histologically proven to be the material of choice for regeneration. However, platelet-rich fibrin (PRF) has been said to have several properties that aid in healing and regeneration. Hence, this study focuses on the regenerative capacity of PRF when compared with DFDBA. MATERIALS AND METHODS: A total of 40 sites with @entity154 were selected and were assigned to the test group (open flap debridement [OFD] and PRF, n = 20) and the control group (OFD + DFDBA, n = 20). At the test sites, two PRF plugs were placed in the @entity154 after debridement of the site and flap was sutured in place. The parameters measured were @entity92 ( @entity92 ), relative attachment level (RAL), and gingival marginal level (GML). These parameters were measured just before surgery (baseline) and at 6 months postsurgery. The changes in @entity92 , RAL, and GML were analyzed at baseline and postsurgically after 6 months in each group with paired t-test and between the two groups with unpaired t-test. RESULTS: The mean reduction in @entity92 after 6 months in the test PRF group is 3.67    1.48 mm where in control DFDBA group is 3.70    1.78 mm. Gain in RAL in the test PRF group is 2.97    1.42 mm where in control DFDBA group, it is 2.97    1.54 mm. Gingival margin migrated apically in the test PRF group by 0.43    1.31 mm where in control DFDBA group by 0.72    2.3 mm. It was seen that the differences in terms of @entity92 (P = 0.96), RAL (P = 1.00) and GML (P = 0.62) were not significant. CONCLUSION: Platelet-rich fibrin has shown significant results after 6 months, which is comparable to DFDBA for periodontal regeneration in terms of clinical parameters. Hence, it can be used in the treatment of @entity154 .

title: Comparative evaluation of platelet-rich fibrin with demineralized freeze-dried bone allograft in periodontal XXXX : A randomized controlled clinical study.

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['intrabony defect', 'intrabony defects', 'infrabony defects']

entities_list: @entity92 :: ('MESH:D007222', 'Disease') :: ['PD', 'probing depth']

answer: @entity154 :: (MESH:D000013,Disease) :: ['infrabony defects']


abstract: PURPOSE: To assess the prevalence of @entity726 in @entity1 with @entity1714 defined as myopic refractive error of >-8 diopters or axial length >= 26.5 mm. METHODS: The hospital-based observational study included 172 @entity1 (336 eyes) with a mean age of 61.9  12.3 years and mean axial length of 30.1  2.3 mm (range: 24.7-39.1mm). Glaucomatous-type optic discs were defined by glaucomatous optic disc appearance. @entity726 was defined by glaucomatous optic disc appearance and @entity227 not corresponding with myopic macular changes. RESULTS: Larger disc area (mean: 3.18  1.94 @entity202 ) was associated with longer axial length (P<0.001; standardized correlation coefficient: 0.45). @entity726 was detected in 94 (28%; 95% Confidence intervals: 23%, 33%) eyes. In multivariate analysis, @entity726 prevalence was 3.2 times higher (P<0.001) in megalodiscs (>3.79 @entity202 ) than in normal-sized discs or small discs (<1.51 @entity202 ) after adjusting for older age. Axial length was not significantly (P = 0.38) associated with @entity726 prevalence in that model. @entity726 prevalence increased by a factor of 1.39 for each increase in optic disc area by one @entity202 . Again, axial length was not significantly (P = 0.38) associated with @entity726 prevalence when added to this multivariate model. CONCLUSION: Within highly myopic individuals, @entity726 prevalence increased with larger optic disc size beyond a disc area of 3.8 @entity202 . Highly myopic megalodiscs as compared to normal sized discs or small discs had a 3.2 times higher risk for glaucomatous @entity1781 . The increased @entity726 prevalence in axial @entity1714 was primarily associated with @entity1714 associated disc enlargement and not with axial elongation itself.

title: Glaucomatous-Type Optic Discs in High XXXX .

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['glaucomatous Goldmann visual field defects']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['Glaucoma', 'glaucoma']

entities_list: @entity1781 :: ('MESH:D009901', 'Disease') :: ['optic nerve neuropathy']

entities_list: @entity1714 :: ('MESH:D009216', 'Disease') :: ['axial myopia', 'high myopia']

answer: @entity1714 :: (MESH:D009216,Disease) :: ['Myopia']


abstract: An improved method of removing @entity35 corneal endothelial sheets for study of endothelial pathology is described. The method was validated by examining morphological changes and changes in expression of major histocompatibility complex (MHC) and @entity1590 on endothelium undergoing immunological rejection. PVG strain @entity35 received LEW strain corneal transplants or corneal isografts. Just prior to and during graft rejection, animals were killed, together with a group of untreated animals. The corneal stroma was injected with dispase or PBS, the cornea was carefully removed, fixed in @entity1324 and the endothelium was gently peeled off and flattened on to a glass slide. Morphological changes, together with MHC class I, class II and @entity1590 expression were visualised by immuno-histochemical staining and quantified by image analysis. Near complete endothelial sheets were obtained by this method. Because of the thin cell layer, there was minimal background staining, permitting rejection-associated changes to be clearly seen. MHC class I expression on normal endothelium was low and not significantly increased on endothelial cells of allografts at the time of rejection compared with controls (P = 0.1). MHC class II and @entity1590 were induced de novo, expression being significantly higher on allografts than on isografts (P = 0.004 for MHC class II and P = 0.01 for @entity1590 ). MHC class I and II and @entity1590 were expressed on many infiltrating cells. Thus, this preparation method permits clear identification of the distribution and morphology of infiltrating cells and other mediators of the immune response in the entire donor endothelium. It confirms that MHC class I expression is low during rejection, while MHC class II and ICAM-I are induced de novo and strongly expressed.

title: An improved method for examining the corneal endothelium during graft rejection in the XXXX .

entities_list: @entity1590 :: ('25464(Tax:10116)', 'Gene') :: ['ICAM-1', 'intercellular adhesion molecule (ICAM)-1']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: BACKGROUND: @entity1 with a shunted @entity1276 are at highest risk for developing an immediate type @entity566 to latex. Limited data are available for preventive or therapeutical approaches. OBJECTIVE: To evaluate the effectiveness of latex avoidance, with special regard to status of sensitization and compliance. METHODS: In 1995, 131 @entity1 with a shunted @entity1276 were screened for sensitization to latex by skin prick test and determination of specific IgE. @entity1 and parents were instructed on latex-avoiding strategies. Hospital physicians, family doctors and dentists were advised to perform further surgical and other medical interventions under latex-free conditions. In 2000, 100 of these 131 @entity1 were re-evaluated according to the same testing procedures. Special attention was directed at the extent prophylaxis had been performed. RESULTS: In 1995, 30/100 @entity1 re-evaluable in 2000 proved sensitized to latex, 70 had negative testing results. In 2000, 64/70 @entity1 were still negative, six had meanwhile developed latex-specific IgE. Seven out of thirty subjects with former positive testing had changes within the same RAST-class, 20 showed a decline of at least one RAST-class, whereas in three cases an increase of latex-specific IgE was found. However, only 34 @entity1 , mainly those being already sensitized, had thoroughly followed both medical and private prophylaxis. Within this group, 16 subjects (47.1%) had improved and another nine (26.5%) were still negative. Only three (8.8%) already previously sensitized @entity1 presented with a further increase of latex-specific IgE. Medical prevention contributed more to the outcome than home prevention. No statistically significant correlation with latex-avoidance was observed, however, in previously unsensitized subjects. Underlying disease, @entity402 , number of operations, and age did not prove as significant variables. CONCLUSION: Secondary prevention results in a decrease of specific IgE in latex-sensitized @entity1 with @entity1276 . This is due to medical more than home prophylaxis. Sensitization obviously occurs mainly in early childhood, thus primary prevention remains to be the main target.

title: Outcome of a latex avoidance program in a high-risk population for latex XXXX - a five-year follow-up study.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'Children']

entities_list: @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus']

answer: @entity566 :: (MESH:D006967,Disease) :: ['allergy']


abstract: OBJECTIVE: The aim of this study was to determine the accuracy of exercise echocardiography (EE) for detecting @entity1188 ( @entity1188 ) @entity850 and predicting functional recovery early after @entity583 ( @entity583 ). BACKGROUND: @entity452 stress echocardiography is widely used for identifying jeopardized myocardium. The clinical usefulness of a biphasic response detected during EE has never been investigated. METHODS: A total of 114 consecutive @entity1 with a first @entity583 and > or = 2 dyssynergic segments in the infarct-related territory underwent semi-supine continuous EE 6 +/- 2 days after @entity583 . Quantitative coronary angiography was performed in all @entity1 after EE. A follow-up echocardiogram was obtained one month later. RESULTS: Ninety-seven @entity1 had significant (> or = 50%) @entity1188 @entity850 , and 26 had multivessel disease. Residual @entity63 was identified in 77 @entity1 (biphasic response in 62 and worsening response in 15). The sensitivity and specificity of @entity63 during EE for predicting @entity1188 @entity850 were 75% and 76%, respectively. The sensitivity of a biphasic response was higher than the sensitivity of a worsening response (61% vs. 14%, p < 0.0001). @entity854 induced in other vascular territories were specific (97%) and moderately sensitive (62%) for the detection of multivessel disease. Functional recovery was observed in 75 @entity1 . Two independent variables predicted contractile recovery: contractile reserve during EE (p < 0.0001) and elective angioplasty of the @entity1188 (p = 0.002). A biphasic response, but not sustained improvement, predicted reversible dysfunction (73% vs. 9%, p < 0.0001). CONCLUSIONS: A biphasic response can be detected during exercise. Exercise echocardiography is an accurate tool for detecting @entity1188 @entity850 and predicting functional improvement early after @entity583 .

title: Detection and clinical usefulness of a biphasic response during exercise echocardiography early after XXXX .

entities_list: @entity452 :: ('MESH:D004280', 'Chemical') :: ['Dobutamine']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['Wall motion abnormalities']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct-related artery', 'IRA']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: We examined the neuroprotective action of a standardized extract of @entity4044 leaves ( @entity12689 ) in permanent and transient @entity2500 models in @entity35 . Forty-four animals were given either @entity12689 (50-200 mg/kg) or vehicle intraperitoneally, 1 hr before permanent @entity2500 , to evaluate the dose-response effects. An additional 58 animals received @entity12689 (200 mg/kg) or vehicle, 0.5- 4 hr after permanent @entity2500 , for establishing the therapeutic window. Delayed treatment was also employed in 110 animals treated with either @entity12689 (100-200 mg/kg) or vehicle at 2-3 hr following transient focal @entity2806 induced by @entity2500 for 2 hr. Neurobehavioral scores were determined 22-24 hr after permanent @entity2500 and either 3 or 7 days after transient @entity2500 , and @entity4798 volumes were measured upon sacrifice. Local cortical blood flow (LCBF) was serially measured in a subset of animals receiving @entity12689 (100-200 mg/kg) or vehicle, 0.5 hr and 2 hr after permanent and transient @entity2500 , respectively. Relative to vehicle-treated controls, @entity35 pretreated with @entity12689 (100 and 200 mg/kg) had significantly reduced @entity1188 volumes, by 36% and 49%, respectively, and improved sensory behavior (P < 0.05). Delayed treatment with @entity12689 also significantly reduced @entity4798 , by 20-29% and 31%, when given up to 2 and 3 hr following transient and permanent @entity2500 , respectively, whereas improved neurobehavioral scores were noted up to 2 hr after the onset of @entity2500 (P < 0.05). LCBF was significantly improved in the ipsilateral cortex following the @entity12689 treatment, whereas a higher dose showed a more sustained effect. In conclusion, @entity12689 protected against transient and permanent focal @entity2806 and was effective after a prolonged reperfusion period even when therapy is delayed up to 2 hr. This neuroprotection may be at least partially attributed to the beneficial effects of selectively improved LCBF in the area at risk of @entity1188 .

title: Acute administration of @entity4044 extract ( @entity12689 ) affords neuroprotection against permanent and transient focal XXXX in @entity35 .

entities_list: @entity4798 :: ('MESH:D020520', 'Disease') :: ['brain infarction']

entities_list: @entity2806 :: ('MESH:D002545', 'Disease') :: ['cerebral ischemia']

entities_list: @entity2500 :: ('MESH:D020244', 'Disease') :: ['MCA occlusion', 'middle cerebral artery (MCA) occlusion']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct', 'infarction']

entities_list: @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats']

entities_list: @entity4044 :: ('3311', 'Species') :: ['Ginkgo biloba']

answer: @entity2806 :: (MESH:D002545,Disease) :: ['cerebral ischemia']


abstract: PURPOSE: @entity3089 ( @entity3090 ) is an antioxidant agent derived from green tea. Because it has chemopreventive and anti-invasive effect against various @entity5 cells, @entity3090 can be used to inhibit proliferation and invasion of @entity201 ( @entity201 ) cells. METHODS: The anticancer effects of @entity3090 were studied using @entity1 @entity201 cells (HuCC-T1). Apoptosis was analyzed by Western blotting. Invasion and migration of @entity5 cells were assessed with Matrigel(  ) and wound healing assays. An animal @entity5 xenograft model of HuCC-T1 was used to study the in vivo antitumor activities of @entity3090 . RESULTS: @entity3090 effectively inhibited the growth of HuCC-T1 cells with no adverse effects on the viability of 293T cells. @entity3090 induced apoptotic cell death at 5   g/mL concentration. It inhibited the expression of mutant @entity876 and induced apoptotic molecular signals such as @entity589 / @entity588 , Caspase, and @entity4674 . Furthermore, @entity3090 dose-dependently inhibited the activity of @entity1476 /9, invasion, and migration. In the animal @entity5 xenograft model of HuCC-T1 cells, @entity3090 was subcutaneously administered beside the @entity5 for local treatment. @entity3090 efficiently inhibited growth of the @entity5 and suppressed carcinogenic molecular signals such as @entity125 , @entity5379 , and proliferating cell nuclear antigen. CONCLUSION: @entity3090 induced apoptosis of @entity5 cells without adverse effects on normal cells. @entity3090 inhibited growth, invasion, and migration of HuCC-T1 cells. We suggest @entity3090 as a promising candidate for local treatment of @entity201 .

title: Anticancer activities of XXXX against @entity201 cells.

entities_list: @entity1476 :: ('4313', 'Gene') :: ['matrix metalloproteinase (MMP)-2']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity3089 :: ('MESH:C045651', 'Chemical') :: ['Epigallocatechin-3-gallate']

entities_list: @entity201 :: ('MESH:D018281', 'Disease') :: ['cholangiocarcinoma', 'CCA']

answer: @entity3089 :: (MESH:C045651,Chemical) :: ['epigallocatechin-3-gallate']


abstract: BACKGROUND: Constitutive activation of @entity2467 receptor @entity669 kinase is critical in the pathogenesis of @entity674 . @entity2213 , a selective @entity669 kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against @entity5 . METHODS: We conducted an open-label, randomized, multicenter trial to evaluate the activity of @entity2213 in @entity1 with advanced @entity674 . We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of @entity1 . RESULTS: A total of 147 @entity1 were randomly assigned to receive 400 mg or 600 mg of @entity2213 daily. Overall, 79 @entity1 (53.7 percent) had a partial response, 41 @entity1 (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 @entity1 (4.8 percent). No @entity1 had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to @entity2213 was noted in 20 @entity1 (13.6 percent). Therapy was well tolerated, although mild-to-moderate @entity4 , @entity294 , and @entity1295 were common. Gastrointestinal or @entity548 occurred in approximately 5 percent of @entity1 . There were no significant differences in toxic effects or response between the two doses. @entity2213 was well absorbed, with pharmacokinetics similar to those reported in @entity1 with @entity1860 . CONCLUSIONS: @entity2213 induced a sustained objective response in more than half of @entity1 with an advanced unresectable or metastatic @entity674 . Inhibition of the @entity2467 signal-transduction pathway is a promising treatment for advanced @entity674 , which resist conventional chemotherapy.

title: Efficacy and safety of XXXX mesylate in advanced @entity674 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['intraabdominal hemorrhage']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['such tumors']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity674 :: ('MESH:D046152', 'Disease') :: ['gastrointestinal stromal tumors', 'gastrointestinal stromal tumor']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

entities_list: @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib', 'Imatinib mesylate', 'Imatinib']

entities_list: @entity1860 :: ('MESH:D015464', 'Disease') :: ['chronic myeloid leukemia']

answer: @entity2213 :: (MESH:C097613,Chemical) :: ['imatinib']


abstract: UNASSIGNED: Purpose To evaluate the efficacy and safety of a @entity19859 -based combination (CLARA) versus conventional high-dose @entity2592 (HDAC) as postremission chemotherapy in younger patients with @entity3052 ( @entity3052 ). Patients and Methods Patients age 18 to 59 years old with intermediate- or unfavorable-risk @entity3052 in first remission and no identified donor for allogeneic @entity8 ( @entity8 ) were eligible. Two hundred twenty-one patients were randomly assigned to receive three CLARA or three HDAC consolidation cycles. The primary end point was @entity4557 ( @entity4557 ). To handle the confounding effect of @entity8 that could occur in patients with late donor identification, hazard ratios (HRs) of events were adjusted on the time-dependent treatment * @entity8 interaction term. Results At 2 years, @entity4557 was 58.5% (95% CI, 49% to 67%) in the CLARA arm and 46.5% (95% CI, 37% to 55%) in the HDAC arm. Overall, 110 patients (55 in each arm) received @entity8 in first remission. On the basis of a multivariable Cox-adjusted treatment * @entity8 interaction, the HR of CLARA over HDAC before or in absence of @entity8 was 0.65 (95% CI, 0.43 to 0.98; P = .041). In a sensitivity analysis, when patients who received @entity8 in first remission were censored at @entity8 time, 2-year @entity4557 was 53.3% (95% CI, 39% to 66%) in the CLARA arm and 31.0% (95% CI, 19% to 43%) in the HDAC arm (HR, 0.63; 95% CI, 0.41 to 0.98; P = .043). Gain in @entity4557 could be related to the lower cumulative incidence of relapse observed in the CLARA arm versus the HDAC arm (33.9% v 46.4% at 2 years, respectively; cause-specific HR, 0.61; 95% CI, 0.40 to 0.94; P = .025). CLARA cycles were associated with higher hematologic and nonhematologic @entity137 than HDAC cycles. Conclusion These results suggest that CLARA might be considered as a new chemotherapy option in younger patients with @entity3052 in first remission.

title: Randomized Phase II Study of @entity19859 -Based Consolidation for Younger Adults With XXXX in First Remission.

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['stem-cell transplantation', 'SCT']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity4557 :: ('MESH:D012008', 'Disease') :: ['RFS', 'relapse-free survival']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML']

entities_list: @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine']

entities_list: @entity19859 :: ('MESH:C068329', 'Chemical') :: ['clofarabine']

answer: @entity3052 :: (MESH:D015470,Disease) :: ['Acute Myeloid Leukemia']


abstract: The combination of @entity3118 (FDR), high dose @entity2592 and @entity1261 (FLAG) with or without @entity8779 ( @entity11059 ) was used in the treatment of poor risk acute @entity1778 or @entity2590 ( @entity2590 ) in a single centre experience. A total of 105 @entity1 were treated over a 4-year period with 59% achieving a complete remission (CR); no statistical difference observed between FLAG and FLAG-Ida. For @entity1 responding to FLAG +/- Ida, the median event-free survival (EFS) was 11 months and 23% at 5 years. Such @entity1 proceeded either to further chemotherapy or a haematopoietic stem cell transplant (HSCT). The median EFS (13 months vs. 8 months) and projected 5-year survival (37% vs. 13%) of @entity1 undergoing HSCT was significantly better than those who did not (P = 0.021). In all, 14 of 72 @entity1 remain alive in continuing CR (median duration 43 months) with 10 of 31 having had a HSCT vs. four of 41 that did not (P = 0.033). Both regimens were well tolerated, with the majority of @entity1 experiencing grade 1 or less non-haematological @entity137 (mainly @entity390 and @entity391 ). The median time to neutrophil and platelet recovery was 28 and 31 d, respectively. No significant differences were seen with the addition of ida. There was a 17% incidence of treatment-related deaths, of which 39% was caused by @entity3 . The results show that FLAG +/- Ida is an effective and well-tolerated remission induction regimen for poor risk @entity1778 and @entity2590 .

title: @entity3118 , @entity2592 , XXXX with or without @entity8779 in the treatment of high risk acute @entity1778 or @entity2590 syndromes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1261 :: ('1440', 'Gene') :: ['granulocyte colony stimulating factor']

entities_list: @entity8779 :: ('MESH:D015255', 'Chemical') :: ['idarubicin']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome', 'MDS']

entities_list: @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine']

entities_list: @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukaemia']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['invasive aspergillus infection']

answer: @entity1261 :: (1440,Gene) :: ['granulocyte-colony stimulating factor']


abstract: BACKGROUND: @entity2753 secondary to the @entity6085 is an uncommon complication of treatment with the new class of antidepressant agents, the selective @entity750 reuptake inhibitors. The risk of @entity2753 seems to be highest during the first weeks of treatment particularly, in elderly females and in @entity1 with a lower body weight. CASE PRESENTATION: A 61-year-old @entity6 male was admitted to the hospital because of malaise, progressive @entity911 , and a tonic/clonic @entity410 two weeks after starting @entity837 , 20 mg/day. On physical examination the @entity1 was euvolemic and had no evidence of @entity5 , @entity8 . Laboratory tests results revealed @entity2753 , serum hypoosmolality, urine hyperosmolarity, and an elevated urine @entity1372 concentration, leading to the diagnosis of inappropriate secretion of antidiuretic hormone. @entity837 was discontinued and fluid restriction was instituted. The @entity1 was discharged after serum @entity1372 increased from 124 mmol/L to 134 mmol/L. Two weeks after discharge the @entity1 denied any new @entity410 , @entity911 or malaise. At that time his serum @entity1372 was 135 mmol/L. CONCLUSIONS: Because the use of @entity750 reuptake inhibitors is becoming more popular among elderly @entity308 @entity1 the present paper and other reported cases emphasize the need of greater awareness of the development of this serious complication and suggest that @entity1372 serum levels should be monitored closely in elderly @entity1 during treatment with @entity837 .

title: Severe symptomatic @entity2753 during XXXX therapy--a case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['cardiac, renal, hepatic, adrenal or thyroid disease']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressed']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy']

entities_list: @entity837 :: ('MESH:D015283', 'Chemical') :: ['citalopram', 'Citalopram']

entities_list: @entity911 :: ('MESH:D003221', 'Disease') :: ['confusion']

entities_list: @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin']

entities_list: @entity6085 :: ('MESH:D007177', 'Disease') :: ['syndrome of inappropriate secretion of antidiuretic hormone']

entities_list: @entity2753 :: ('MESH:D007010', 'Disease') :: ['hyponatremia', 'Hyponatremia']

answer: @entity837 :: (MESH:D015283,Chemical) :: ['citalopram']


abstract: In view of the high prevalence of @entity3147 in hospitals as shown by some studies and in the light of its direct impact on the increase in morbidity and mortality among hospitalized @entity1 , it is necessary to ensure the early identification of this condition. This would allow appropriate nutritional treatment to be instituted as soon as possible for @entity1 at risk who require it. The present multi-centric study included the participation of hospitals in the northern region of the country which have a Nutrition Unit, with use of the Overall Subjective Assessment and a few basic parameters. The study analyzed the nutritional status on admission of 620 @entity1 hospitalized in the Internal Medicine and General Surgery areas during the months of December, 1999, January, February and March, 2000. We detected moderate @entity3147 or suspected @entity3147 in 20% of the @entity1 studied and severe @entity3147 in 18.2%, with a greater incidence in Internal Medicine. Malnutrition was mainly evidenced by weight loss of more than 5% and a reduction in subcutaneous fat and muscle mass. In addition, there are functional limitations on performing everyday activities. Changes in dietary intake were present in 40.8% of the @entity1 . The associated gastro-intestinal symptoms included @entity448 , which affected 37.7% of the group studied. Malnutrition is most frequently linked with @entity166 , problems in circulation and with the digestive apparatus. We feel that the Overall Subjective Assessment, together with the measurement of height and weight, should be used systematically with @entity1 on admission, as it is a simple and effective method for the identification of @entity1 with nutritional risk.

title: [Detection of XXXX on admission to hospital].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious diseases']

entities_list: @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia']

entities_list: @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition']

answer: @entity3147 :: (MESH:D044342,Disease) :: ['malnutrition']


abstract: The intraoperative use of local anesthetic agents to decrease @entity282 has been used in many types of procedures. Most of these techniques involve needle injection of anesthetic and result in a low but troublesome incidence of complications. In this study, we evaluated the reliability, safety, and efficacy of a technique emphasizing bathing of tissues with anesthetic rather than needle injection for relieving @entity282 . Thirty consecutive @entity1 undergoing outpatient elective inguinal herniorrhaphy with general anesthetic were prospectively randomized into four treatment groups. Group 1 received 0.5 per cent @entity1341 plus @entity1425 1 to 200,000; group 2, 0.5 per cent @entity1341 ; group 3, normal saline solution, and group 4, no treatment. At the end of the repair, one-third of the test solution (approximately 5 milliliters) was bathed along the spermatic cord throughout its length in the inguinal canal. The external oblique aponeurosis was closed superficial to the cord structures and another one-third of the solution was instilled into the wound. Just prior to the end of skin closure the remaining solution was instilled subcutaneously. No needles were used to instill the solutions and they were not suctioned or removed from the wound. Data collection consisted of an analog type of @entity1 questionnaire allowing subjective assessment of @entity282 at various time intervals during the first 20 hours postoperatively. @entity158 medication provided was @entity15848 , 100 milligrams and @entity1443 , 650 milligrams every three hours as needed. Total doses of @entity158 medication for the study period and the time to first @entity158 medication requirement were obtained. Results were analyzed using analysis of variance, and Wilcoxon ranked sums test. @entity1 in group 1 (0.5 per cent @entity1341 with @entity1425 ) exhibited significantly less @entity158 than those in groups 3 (saline solution) and 4 (control) for more than 12 hours postoperatively. @entity1 in group 2 (0.5 per cent @entity1341 ) likewise experienced less @entity158 than those in groups 3 and 4 through seven hours. The @entity1 receiving saline solution were not significantly different than those in the control group throughout. Objectively, groups 1 and 2 required fewer total doses of @entity158 medication and waited longer before requesting oral @entity158 medication postoperatively compared with those in the control group. No complications occurred that could be attributed to the technique. The results of this study indicate that the bathing of wounds with 0.5 per cent @entity1341 with or without @entity1425 1:200,000 is a safe and effective method of decreasing @entity282 for several hours in @entity1 undergoing elective inguinal herniorrhaphy.(ABSTRACT TRUNCATED AT 400 WORDS)

title: The use of XXXX in elective inguinal herniorrhaphy as a fast and safe technique for relief of @entity282 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['epinephrine']

entities_list: @entity1341 :: ('MESH:D002045', 'Chemical') :: ['bupivacaine']

entities_list: @entity15848 :: ('MESH:D011431', 'Chemical') :: ['propoxyphene']

entities_list: @entity1443 :: ('MESH:D000082', 'Chemical') :: ['acetaminophen']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain']

answer: @entity1341 :: (MESH:D002045,Chemical) :: ['bupivacaine']


abstract: PURPOSE: To estimate prevalence of @entity227 ( @entity227 ) loss in superior and inferior hemifields in binocular VFs in a large sample of @entity1 with @entity726 . DESIGN: Retrospective cohort study. @entity1 : @entity726 @entity1 and suspects attending 4 regionally different secondary-care eye clinics in the United Kingdom. METHODS: Binocular integrated visual fields (IVFs) using a best location method were constructed for 16 642 @entity1 with bilateral @entity227 . A significant @entity227 was defined as 3 or more @entity227 locations less than a certain sensitivity threshold, such as 20 dB. @entity1 were classified as having a @entity227 in the inferior hemifield, superior hemifield, both hemifields, or neither hemifield. The criteria for number of locations and sensitivity threshold (in decibels) were varied across a large range of values. In addition, factor analysis was applied to the sensitivity values (in decibels) of the IVFs to determine common defect patterns in an automated fashion. MAIN OUTCOME MEASURES: Ratio of @entity1 with binocular @entity227 defects in the superior compared with the inferior areas of the IVF. RESULTS: Estimates of the ratio of @entity1 having binocular @entity227 defects in the superior compared with the inferior region of the IVF ranged from 2.1 (95% confidence interval, 2.1-2.4) to as high as 5.1 (95% confidence interval, 4.7-5.5), depending on the defect criteria used. Fewer than 10% of those @entity1 exhibiting relatively early binocular @entity227 had a defect confined to the inferior region only. Common patterns of binocular @entity227 were dominated chiefly by superior hemifield defects. CONCLUSIONS: In a clinical population of @entity1 with measurable @entity227 in both eyes, superior-only binocular @entity227 is more common than inferior-only loss. These estimates, derived from large collections of electronic medical records, are useful for interpreting findings about location of binocular @entity227 impacting everyday activities and examining @entity227 in @entity726 .

title: Patterns of Binocular Visual Field Loss Derived from Large-Scale XXXX Data from @entity726 Clinics.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PARTICIPANTS']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual disability', 'visual field', 'VF loss', 'VF defect', 'VF']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['Glaucoma', 'bilateral glaucoma', 'glaucoma']

answer: @entity1 :: (9606,Species) :: ['Patient']


abstract: Extruded RTE snacks were prepared from flour blends made with @entity4336 flour, Bengal gram flour, roots and tuber flours in a proportion of 60-80: 20: 20 respectively and moisture was adjusted to 17-20  %. The roots and tubers flours were developed from @entity415 ( @entity415 ), yam (Dioscorea spp.), sweet potato (Ipomoea batatas L.), @entity20737 (Colocassia esculenta) and beet root (Beta vulgaris). Different formulations were extruded at 80        5    C (heater I) and 95-105    C (heater II) temperature, 300-350  rpm screw speed, 100        10    C die temperature and 15        2  kg/h feed rate. The exit diameter of the circular die was 3  mm. Sensory acceptability, physical parameters and nutrient analysis along with storage stability of the products was conducted. The fiber and energy content of the RTE extruded snack improved in experimental samples prepared using root and tuber flours. A serving of 100  g of the snack can provide more than 400  Kcal and 10  g of protein. The overall acceptability of RTE extruded products made with @entity415 and @entity20737 were highly acceptable compared to yam and sweet potato. The study demonstrates utilization of roots and tuber flours as potential and diverse ingredients to enhance the appearance and nutritional properties in RTE extruded snack.

title: Development of extruded Ready-To-Eat (RTE) snacks using XXXX , black gram, roots and tuber flour blends.

entities_list: @entity415 :: ('4113', 'Species') :: ['Solanum tuberosum', 'potato']

answer: @entity4336 :: (381124,Species) :: ['corn']


abstract: UNASSIGNED: 9650 Background: Poor quality of life and poor survival of @entity5 @entity1 were independently predicted by an alteration of the rest-activity (RA) and/or @entity701 circadian rhythms. This disturbance could be mediated by high levels of @entity5 - or host- derived growth factors, known to modulate circadian clock function. METHODS: @entity7790 , @entity310 and @entity650 levels were determined with ELISA in sera from 80 @entity14 @entity1 whose rhythms in RA (wrist actimetry for 3 d) and @entity701 (serum drawn at 08:00 and 16:00 ) were prospectively studied (Mormont et al. Clin Cancer Res 2000). The samples were selected from @entity1 having rhythmic (group 1, n=40) or damped (group 2, n=40) RA pattern, as assessed with autocorrelation for a period of 24 h (r24). Groups were compared with Kruskall-Wallis test. Correlations between factor concentrations and circadian parameters were explored with Spearman    test. RESULTS: Median RA r24 were 0.56 (range, 0.47 to 0.77) in group 1 and 0.22 (0.03 to 0.35) in group 2 (p < 0.0001). Median @entity701 ratio (value at 08:00 / value at 16:00    quartile) were 1.72 [1.48 - 1.98] and 1.60 [1.14 - 1.77] respectively (p = 0.031). Median (   quartile) dichotomy index (I<O), an integrated estimate of RA pattern and sleep quality, was 98.5 % [97.0 - 99.7] in group 1 and 91.4 % [82.1 - 96.7] in group 2 (p < 0.0001). @entity7790 , @entity310 and @entity650 serum levels (pg/ml) were significantly lower in group 1 as compared to group 2 (Table) and negatively correlated with I<O (r = - 0.45, p < 0.0001; r = -0.27, p = 0.022; r = -0.37, p = 0.001, respectively). @entity650 levels were also negatively correlated with @entity701 rhythm estimate (r = - 0.31, p = 0.005). CONCLUSIONS: Altered circadian function was associated with increased production of @entity5 -derived growth factors, suggesting a mechanism through which a @entity5 can promote its own development via the disturbance of host physiology. Supported by: ARTBC; J W Sieg fund. [Figure: see text] No significant financial relationships to disclose.

title: High serum @entity7790 , @entity310 and @entity650 correlate with abnormal circadian rhythms in @entity1 with @entity14 ( XXXX ).

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol']

answer: @entity14 :: (MESH:D015179,Disease) :: ['MCC']


abstract: UNASSIGNED: Several studies have demonstrated that the @entity17777 proto  -oncogene and its ligand, stem cell factor, are important in the development of @entity565 . @entity6711 ( @entity6711 ; @entity7130 ) allergens are a major trigger in the development and exacerbation of @entity565 . @entity6711 allergens can induce the activation of @entity17777 in dendritic cells (DCs), leading to the development of @entity56 . Previous studies have demonstrated that activation of @entity8932 ( @entity8932 ) evokes a T  helper (Th)2 immune response and promotes experimental @entity565 . The aim of the present study was to assess whether @entity6711 mediates the activation of @entity17777 in DCs via @entity8932 . Monocyte  -derived DCs were generated from C57BL/6 @entity19 , and cultured with interleukin (IL)  -4 and granulocyte  -macrophage colony  -stimulating factor. The DCs were then sensitized with @entity6711 (10    g/ml) for 72  h. @entity8932  -specific small interfering  (si)RNA was used to silence and inhibit the expression of @entity8932 in the DCs. The expression levels of @entity17777 ( @entity8271 / @entity11787 ) were measured, by analyzing the DC culture supernatant for the presence of @entity777 and IL  -12. Inhibition of @entity8932 using specific siRNA downregulated the expression of @entity17777 in the @entity6711  -activated DCs. In addition, silencing of @entity8932 inhibited the expression of @entity8271 / @entity11787 , decreased the production of @entity777 , and increased the production of IL  -12. These results indicated that @entity67679 are important in the activation of @entity17777 by @entity6711 in DCs.

title: @entity6711 allergens mediate the activation of XXXX in dendritic cells via Toll  -like receptor 2.

entities_list: @entity7130 :: ('6956', 'Species') :: ['Dermatophagoides  pteronyssinus']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic asthma']

entities_list: @entity6711 :: ('MESH:D008924', 'Disease') :: ['HDM', 'House dust mite']

answer: @entity17777 :: (16590(Tax:10090),Gene) :: ['c  -kit']